These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15460638)

  • 21. Development of a vaccine against serogroup B has been the main scientific challenge. Preface.
    Rappuoli R; Pizza M; Black S; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global epidemiology of meningococcal disease.
    Harrison LH; Trotter CL; Ramsay ME
    Vaccine; 2009 Jun; 27 Suppl 2():B51-63. PubMed ID: 19477562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic.
    Lennon D
    N Z Med J; 2008 Mar; 121(1270):110-2. PubMed ID: 18364765
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
    Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
    Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neisseria meningitidis. The pathophysiological role of lipopolysaccharides in association with meningococcal disease and septic shock].
    Pedersen MØ; Pedersen DS; Pedersen M; Penkowa M
    Ugeskr Laeger; 2008 Feb; 170(6):421-6. PubMed ID: 18252172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003.
    Can Commun Dis Rep; 2006 Apr; 32(8):97-107. PubMed ID: 16685767
    [No Abstract]   [Full Text] [Related]  

  • 31. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
    Oster P; Lennon D; O'Hallahan J; Mulholland K; Reid S; Martin D
    Vaccine; 2005 Mar; 23(17-18):2191-6. PubMed ID: 15755593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meningococcal disease--outbreak in Delhi.
    Sachdeva A; Kukreja S; Jain V; Dutta AK
    Indian Pediatr; 2005 Jun; 42(6):547-56. PubMed ID: 15995271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005.
    Can Commun Dis Rep; 2007 Jun; 33(10):1-15. PubMed ID: 17691125
    [No Abstract]   [Full Text] [Related]  

  • 34. Meningococcal disease and prevention at the Hajj.
    Borrow R
    Travel Med Infect Dis; 2009 Jul; 7(4):219-25. PubMed ID: 19717104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.
    O'Hallahan J; Lennon D; Oster P; Lane R; Reid S; Mulholland K; Stewart J; Penney L; Percival T; Martin D
    Vaccine; 2005 Mar; 23(17-18):2197-201. PubMed ID: 15755594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACIP weighs in on meningococcal B vaccines.
    Campos-Outcalt D
    J Fam Pract; 2015 Dec; 64(12):787-9. PubMed ID: 26844997
    [No Abstract]   [Full Text] [Related]  

  • 37. [Coverage of meningococcal infections by local health authorities in Seine-Maritime].
    Sesboüé C
    Arch Pediatr; 2007 Jun; 14(6):544-5. PubMed ID: 17391939
    [No Abstract]   [Full Text] [Related]  

  • 38. Mum's the word: factors that influenced young adults' participation in the New Zealand Meningococcal B immunisation programme.
    Bland M; Clear GM; Grogan A; Hoare K; Waldock J
    N Z Med J; 2009 Dec; 122(1307):30-8. PubMed ID: 20148042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of invasive meningococcal disease in the United States.
    Pelton SI
    Pediatr Infect Dis J; 2009 Apr; 28(4):329-32. PubMed ID: 19333079
    [No Abstract]   [Full Text] [Related]  

  • 40. [The meningococcal vaccine trial 1988-91].
    Kristiansen BE; Brandtzaeg P; Bjorvatn B; Solberg CO
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):192-4. PubMed ID: 19180164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.